Shares of UnitedHealth Group Inc (NYSE:UNH) ended Thursday session in green amid volatile trading. The shares closed up +1.13 points or 0.78% at $141.04 with 3.02 million shares getting traded. Post opening the session at $140.49, the shares hit an intraday low of $140.33 and an intraday high of $141.41 and the price vacillated in this range throughout the day. The company has a market cap of $136.71 billion and the numbers of outstanding shares have been calculated to be 952.39 million shares.
UnitedHealth Group Inc (UNH) will release its financial results for the third quarter of 2016 on Tuesday, October 18, 2016, before the market opens, and will host a teleconference at 8:45 a.m. ET to discuss the results with analysts and investors. This call will be webcast on the Investors page of the company’s web site (www.unitedhealthgroup.com). The replay will be available on the web site or by dialing 1-800-283-4799 through November 1.
Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) ended Thursday session in green amid volatile trading. The shares closed up +0.78 points or 1.55% at $51.23 with 2.97 million shares getting traded. Post opening the session at $50.65, the shares hit an intraday low of $50.60 and an intraday high of $51.45 and the price vacillated in this range throughout the day. The company has a market cap of $51.96 billion and the numbers of outstanding shares have been calculated to be 1.01 billion shares.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) on September 22, 2016 announced SD-809 (deutetrabenazine) showed statistically significant results in the second Phase III registration trial studying the potential of SD-809 for the treatment of tardive dyskinesia (TD). These new results for the AIM-TD trial follow positive results from the ARM-TD trial announced in June 2015. Both ARM-TD and AIM-TD were 12 week treatment studies. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for SD-809 for the treatment of TD in November 2015. Teva expects to make a regulatory submission to the FDA by the end of 2016.
“We are delighted to deliver positive results from a second Phase III study showing the potential for SD-809 to treat the involuntary movements of tardive dyskinesia. This condition is debilitating and often leads to isolation of those affected,” said Michael Hayden, M.D., Ph.D., President of Global R&D and Chief Scientific Officer at Teva, adding that “The study results strengthen our resolve to making this product an option for those patients in need. We are grateful to the trial participants and study investigators who contributed to this study.”